nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—SLC22A1—prostate cancer	0.436	1	CbGaD
Pramipexole—SLC22A2—Estradiol—prostate cancer	0.0185	0.535	CbGbCtD
Pramipexole—SLC22A1—Estradiol—prostate cancer	0.016	0.465	CbGbCtD
Pramipexole—Anxiety—Prednisone—prostate cancer	3.18e-05	8.11e-05	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—prostate cancer	3.17e-05	8.09e-05	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.17e-05	8.08e-05	CcSEcCtD
Pramipexole—Dyspnoea—Docetaxel—prostate cancer	3.16e-05	8.06e-05	CcSEcCtD
Pramipexole—Somnolence—Docetaxel—prostate cancer	3.16e-05	8.04e-05	CcSEcCtD
Pramipexole—Discomfort—Prednisone—prostate cancer	3.15e-05	8.04e-05	CcSEcCtD
Pramipexole—Eye disorder—Epirubicin—prostate cancer	3.15e-05	8.02e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Etoposide—prostate cancer	3.15e-05	8.02e-05	CcSEcCtD
Pramipexole—Tinnitus—Epirubicin—prostate cancer	3.14e-05	8.01e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.13e-05	7.98e-05	CcSEcCtD
Pramipexole—Cardiac disorder—Epirubicin—prostate cancer	3.13e-05	7.97e-05	CcSEcCtD
Pramipexole—Flushing—Epirubicin—prostate cancer	3.13e-05	7.97e-05	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—prostate cancer	3.13e-05	7.97e-05	CcSEcCtD
Pramipexole—Dyspepsia—Docetaxel—prostate cancer	3.12e-05	7.96e-05	CcSEcCtD
Pramipexole—Insomnia—Capecitabine—prostate cancer	3.11e-05	7.92e-05	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—prostate cancer	3.1e-05	7.91e-05	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—prostate cancer	3.09e-05	7.89e-05	CcSEcCtD
Pramipexole—Paraesthesia—Capecitabine—prostate cancer	3.09e-05	7.86e-05	CcSEcCtD
Pramipexole—Decreased appetite—Docetaxel—prostate cancer	3.09e-05	7.86e-05	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—prostate cancer	3.08e-05	7.85e-05	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—prostate cancer	3.07e-05	7.83e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Docetaxel—prostate cancer	3.06e-05	7.81e-05	CcSEcCtD
Pramipexole—Asthenia—Etoposide—prostate cancer	3.06e-05	7.81e-05	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—prostate cancer	3.06e-05	7.81e-05	CcSEcCtD
Pramipexole—Dyspnoea—Capecitabine—prostate cancer	3.06e-05	7.81e-05	CcSEcCtD
Pramipexole—Oedema—Prednisone—prostate cancer	3.06e-05	7.8e-05	CcSEcCtD
Pramipexole—Fatigue—Docetaxel—prostate cancer	3.06e-05	7.8e-05	CcSEcCtD
Pramipexole—Angiopathy—Epirubicin—prostate cancer	3.06e-05	7.79e-05	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—prostate cancer	3.06e-05	7.79e-05	CcSEcCtD
Pramipexole—Nausea—Mitoxantrone—prostate cancer	3.05e-05	7.77e-05	CcSEcCtD
Pramipexole—Immune system disorder—Epirubicin—prostate cancer	3.04e-05	7.76e-05	CcSEcCtD
Pramipexole—Infection—Prednisone—prostate cancer	3.04e-05	7.75e-05	CcSEcCtD
Pramipexole—Mediastinal disorder—Epirubicin—prostate cancer	3.04e-05	7.74e-05	CcSEcCtD
Pramipexole—Constipation—Docetaxel—prostate cancer	3.04e-05	7.73e-05	CcSEcCtD
Pramipexole—Pain—Docetaxel—prostate cancer	3.04e-05	7.73e-05	CcSEcCtD
Pramipexole—Dyspepsia—Capecitabine—prostate cancer	3.02e-05	7.71e-05	CcSEcCtD
Pramipexole—Chills—Epirubicin—prostate cancer	3.02e-05	7.7e-05	CcSEcCtD
Pramipexole—Pruritus—Etoposide—prostate cancer	3.02e-05	7.7e-05	CcSEcCtD
Pramipexole—Shock—Prednisone—prostate cancer	3.01e-05	7.67e-05	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—prostate cancer	3e-05	7.66e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Prednisone—prostate cancer	3e-05	7.65e-05	CcSEcCtD
Pramipexole—Tachycardia—Prednisone—prostate cancer	2.99e-05	7.61e-05	CcSEcCtD
Pramipexole—Decreased appetite—Capecitabine—prostate cancer	2.99e-05	7.61e-05	CcSEcCtD
Pramipexole—Alopecia—Epirubicin—prostate cancer	2.98e-05	7.59e-05	CcSEcCtD
Pramipexole—Skin disorder—Prednisone—prostate cancer	2.97e-05	7.58e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Capecitabine—prostate cancer	2.97e-05	7.56e-05	CcSEcCtD
Pramipexole—Fatigue—Capecitabine—prostate cancer	2.96e-05	7.55e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Prednisone—prostate cancer	2.96e-05	7.54e-05	CcSEcCtD
Pramipexole—Mental disorder—Epirubicin—prostate cancer	2.95e-05	7.52e-05	CcSEcCtD
Pramipexole—Pain—Capecitabine—prostate cancer	2.94e-05	7.49e-05	CcSEcCtD
Pramipexole—Constipation—Capecitabine—prostate cancer	2.94e-05	7.49e-05	CcSEcCtD
Pramipexole—Erythema—Epirubicin—prostate cancer	2.93e-05	7.47e-05	CcSEcCtD
Pramipexole—Malnutrition—Epirubicin—prostate cancer	2.93e-05	7.47e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Docetaxel—prostate cancer	2.92e-05	7.45e-05	CcSEcCtD
Pramipexole—Diarrhoea—Etoposide—prostate cancer	2.92e-05	7.45e-05	CcSEcCtD
Pramipexole—Anorexia—Prednisone—prostate cancer	2.92e-05	7.44e-05	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—prostate cancer	2.91e-05	7.42e-05	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—prostate cancer	2.91e-05	7.41e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Docetaxel—prostate cancer	2.9e-05	7.4e-05	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—prostate cancer	2.89e-05	7.37e-05	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—prostate cancer	2.89e-05	7.37e-05	CcSEcCtD
Pramipexole—Flatulence—Epirubicin—prostate cancer	2.89e-05	7.37e-05	CcSEcCtD
Pramipexole—Tension—Epirubicin—prostate cancer	2.88e-05	7.33e-05	CcSEcCtD
Pramipexole—Dysgeusia—Epirubicin—prostate cancer	2.87e-05	7.32e-05	CcSEcCtD
Pramipexole—Nervousness—Epirubicin—prostate cancer	2.85e-05	7.26e-05	CcSEcCtD
Pramipexole—Back pain—Epirubicin—prostate cancer	2.84e-05	7.23e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Capecitabine—prostate cancer	2.83e-05	7.22e-05	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—prostate cancer	2.83e-05	7.21e-05	CcSEcCtD
Pramipexole—Dizziness—Etoposide—prostate cancer	2.82e-05	7.2e-05	CcSEcCtD
Pramipexole—Muscle spasms—Epirubicin—prostate cancer	2.82e-05	7.19e-05	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—prostate cancer	2.82e-05	7.18e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Capecitabine—prostate cancer	2.81e-05	7.16e-05	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—prostate cancer	2.81e-05	7.16e-05	CcSEcCtD
Pramipexole—Body temperature increased—Docetaxel—prostate cancer	2.81e-05	7.15e-05	CcSEcCtD
Pramipexole—Abdominal pain—Docetaxel—prostate cancer	2.81e-05	7.15e-05	CcSEcCtD
Pramipexole—Chills—Doxorubicin—prostate cancer	2.8e-05	7.13e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Prednisone—prostate cancer	2.79e-05	7.11e-05	CcSEcCtD
Pramipexole—Insomnia—Prednisone—prostate cancer	2.77e-05	7.05e-05	CcSEcCtD
Pramipexole—Vision blurred—Epirubicin—prostate cancer	2.76e-05	7.04e-05	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—prostate cancer	2.76e-05	7.02e-05	CcSEcCtD
Pramipexole—Paraesthesia—Prednisone—prostate cancer	2.75e-05	7e-05	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—prostate cancer	2.73e-05	6.96e-05	CcSEcCtD
Pramipexole—Urticaria—Capecitabine—prostate cancer	2.73e-05	6.96e-05	CcSEcCtD
Pramipexole—Ill-defined disorder—Epirubicin—prostate cancer	2.72e-05	6.94e-05	CcSEcCtD
Pramipexole—Abdominal pain—Capecitabine—prostate cancer	2.72e-05	6.92e-05	CcSEcCtD
Pramipexole—Body temperature increased—Capecitabine—prostate cancer	2.72e-05	6.92e-05	CcSEcCtD
Pramipexole—Vomiting—Etoposide—prostate cancer	2.72e-05	6.92e-05	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—prostate cancer	2.71e-05	6.92e-05	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—prostate cancer	2.71e-05	6.92e-05	CcSEcCtD
Pramipexole—Anaemia—Epirubicin—prostate cancer	2.71e-05	6.91e-05	CcSEcCtD
Pramipexole—Agitation—Epirubicin—prostate cancer	2.7e-05	6.87e-05	CcSEcCtD
Pramipexole—Dyspepsia—Prednisone—prostate cancer	2.69e-05	6.87e-05	CcSEcCtD
Pramipexole—Rash—Etoposide—prostate cancer	2.69e-05	6.86e-05	CcSEcCtD
Pramipexole—Dermatitis—Etoposide—prostate cancer	2.69e-05	6.86e-05	CcSEcCtD
Pramipexole—Headache—Etoposide—prostate cancer	2.68e-05	6.82e-05	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—prostate cancer	2.67e-05	6.82e-05	CcSEcCtD
Pramipexole—Tension—Doxorubicin—prostate cancer	2.66e-05	6.79e-05	CcSEcCtD
Pramipexole—Decreased appetite—Prednisone—prostate cancer	2.66e-05	6.78e-05	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—prostate cancer	2.66e-05	6.77e-05	CcSEcCtD
Pramipexole—Malaise—Epirubicin—prostate cancer	2.65e-05	6.74e-05	CcSEcCtD
Pramipexole—Fatigue—Prednisone—prostate cancer	2.64e-05	6.72e-05	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—prostate cancer	2.64e-05	6.72e-05	CcSEcCtD
Pramipexole—Vertigo—Epirubicin—prostate cancer	2.64e-05	6.72e-05	CcSEcCtD
Pramipexole—Syncope—Epirubicin—prostate cancer	2.63e-05	6.7e-05	CcSEcCtD
Pramipexole—Leukopenia—Epirubicin—prostate cancer	2.63e-05	6.69e-05	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—prostate cancer	2.63e-05	6.69e-05	CcSEcCtD
Pramipexole—Constipation—Prednisone—prostate cancer	2.62e-05	6.67e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Docetaxel—prostate cancer	2.62e-05	6.66e-05	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—prostate cancer	2.61e-05	6.65e-05	CcSEcCtD
Pramipexole—Palpitations—Epirubicin—prostate cancer	2.59e-05	6.61e-05	CcSEcCtD
Pramipexole—Loss of consciousness—Epirubicin—prostate cancer	2.58e-05	6.57e-05	CcSEcCtD
Pramipexole—Cough—Epirubicin—prostate cancer	2.56e-05	6.52e-05	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—prostate cancer	2.56e-05	6.52e-05	CcSEcCtD
Pramipexole—Asthenia—Docetaxel—prostate cancer	2.55e-05	6.49e-05	CcSEcCtD
Pramipexole—Convulsion—Epirubicin—prostate cancer	2.54e-05	6.48e-05	CcSEcCtD
Pramipexole—Nausea—Etoposide—prostate cancer	2.54e-05	6.46e-05	CcSEcCtD
Pramipexole—Hypertension—Epirubicin—prostate cancer	2.53e-05	6.45e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Capecitabine—prostate cancer	2.53e-05	6.45e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Prednisone—prostate cancer	2.52e-05	6.43e-05	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—prostate cancer	2.52e-05	6.42e-05	CcSEcCtD
Pramipexole—Pruritus—Docetaxel—prostate cancer	2.51e-05	6.4e-05	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—prostate cancer	2.51e-05	6.39e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Prednisone—prostate cancer	2.5e-05	6.38e-05	CcSEcCtD
Pramipexole—Arthralgia—Epirubicin—prostate cancer	2.5e-05	6.36e-05	CcSEcCtD
Pramipexole—Chest pain—Epirubicin—prostate cancer	2.5e-05	6.36e-05	CcSEcCtD
Pramipexole—Myalgia—Epirubicin—prostate cancer	2.5e-05	6.36e-05	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—prostate cancer	2.49e-05	6.36e-05	CcSEcCtD
Pramipexole—Anxiety—Epirubicin—prostate cancer	2.49e-05	6.34e-05	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.48e-05	6.32e-05	CcSEcCtD
Pramipexole—Discomfort—Epirubicin—prostate cancer	2.47e-05	6.29e-05	CcSEcCtD
Pramipexole—Asthenia—Capecitabine—prostate cancer	2.47e-05	6.28e-05	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—prostate cancer	2.45e-05	6.24e-05	CcSEcCtD
Pramipexole—Dry mouth—Epirubicin—prostate cancer	2.44e-05	6.22e-05	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—prostate cancer	2.44e-05	6.21e-05	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—prostate cancer	2.43e-05	6.2e-05	CcSEcCtD
Pramipexole—Urticaria—Prednisone—prostate cancer	2.43e-05	6.2e-05	CcSEcCtD
Pramipexole—Pruritus—Capecitabine—prostate cancer	2.43e-05	6.2e-05	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—prostate cancer	2.43e-05	6.19e-05	CcSEcCtD
Pramipexole—Diarrhoea—Docetaxel—prostate cancer	2.43e-05	6.19e-05	CcSEcCtD
Pramipexole—Abdominal pain—Prednisone—prostate cancer	2.42e-05	6.17e-05	CcSEcCtD
Pramipexole—Body temperature increased—Prednisone—prostate cancer	2.42e-05	6.17e-05	CcSEcCtD
Pramipexole—Confusional state—Epirubicin—prostate cancer	2.41e-05	6.15e-05	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—prostate cancer	2.4e-05	6.11e-05	CcSEcCtD
Pramipexole—Oedema—Epirubicin—prostate cancer	2.39e-05	6.1e-05	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—prostate cancer	2.39e-05	6.08e-05	CcSEcCtD
Pramipexole—Infection—Epirubicin—prostate cancer	2.38e-05	6.06e-05	CcSEcCtD
Pramipexole—Cough—Doxorubicin—prostate cancer	2.37e-05	6.04e-05	CcSEcCtD
Pramipexole—Shock—Epirubicin—prostate cancer	2.36e-05	6e-05	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—prostate cancer	2.35e-05	5.99e-05	CcSEcCtD
Pramipexole—Diarrhoea—Capecitabine—prostate cancer	2.35e-05	5.99e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Epirubicin—prostate cancer	2.35e-05	5.98e-05	CcSEcCtD
Pramipexole—Dizziness—Docetaxel—prostate cancer	2.35e-05	5.98e-05	CcSEcCtD
Pramipexole—Thrombocytopenia—Epirubicin—prostate cancer	2.34e-05	5.97e-05	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—prostate cancer	2.34e-05	5.97e-05	CcSEcCtD
Pramipexole—Tachycardia—Epirubicin—prostate cancer	2.34e-05	5.95e-05	CcSEcCtD
Pramipexole—Skin disorder—Epirubicin—prostate cancer	2.33e-05	5.93e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Epirubicin—prostate cancer	2.31e-05	5.9e-05	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—prostate cancer	2.31e-05	5.89e-05	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—prostate cancer	2.31e-05	5.89e-05	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—prostate cancer	2.31e-05	5.89e-05	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—prostate cancer	2.3e-05	5.87e-05	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.29e-05	5.85e-05	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—prostate cancer	2.28e-05	5.82e-05	CcSEcCtD
Pramipexole—Anorexia—Epirubicin—prostate cancer	2.28e-05	5.81e-05	CcSEcCtD
Pramipexole—Dizziness—Capecitabine—prostate cancer	2.27e-05	5.79e-05	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—prostate cancer	2.26e-05	5.76e-05	CcSEcCtD
Pramipexole—Vomiting—Docetaxel—prostate cancer	2.26e-05	5.75e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Prednisone—prostate cancer	2.26e-05	5.75e-05	CcSEcCtD
Pramipexole—Rash—Docetaxel—prostate cancer	2.24e-05	5.7e-05	CcSEcCtD
Pramipexole—Hypotension—Epirubicin—prostate cancer	2.24e-05	5.7e-05	CcSEcCtD
Pramipexole—Dermatitis—Docetaxel—prostate cancer	2.24e-05	5.7e-05	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—prostate cancer	2.23e-05	5.69e-05	CcSEcCtD
Pramipexole—Headache—Docetaxel—prostate cancer	2.22e-05	5.67e-05	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—prostate cancer	2.22e-05	5.64e-05	CcSEcCtD
Pramipexole—Infection—Doxorubicin—prostate cancer	2.2e-05	5.61e-05	CcSEcCtD
Pramipexole—Asthenia—Prednisone—prostate cancer	2.2e-05	5.6e-05	CcSEcCtD
Pramipexole—Vomiting—Capecitabine—prostate cancer	2.18e-05	5.57e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.18e-05	5.56e-05	CcSEcCtD
Pramipexole—Shock—Doxorubicin—prostate cancer	2.18e-05	5.55e-05	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—prostate cancer	2.17e-05	5.54e-05	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—prostate cancer	2.17e-05	5.53e-05	CcSEcCtD
Pramipexole—Rash—Capecitabine—prostate cancer	2.17e-05	5.52e-05	CcSEcCtD
Pramipexole—Pruritus—Prednisone—prostate cancer	2.17e-05	5.52e-05	CcSEcCtD
Pramipexole—Insomnia—Epirubicin—prostate cancer	2.17e-05	5.52e-05	CcSEcCtD
Pramipexole—Dermatitis—Capecitabine—prostate cancer	2.16e-05	5.52e-05	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—prostate cancer	2.16e-05	5.51e-05	CcSEcCtD
Pramipexole—Headache—Capecitabine—prostate cancer	2.15e-05	5.49e-05	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—prostate cancer	2.15e-05	5.48e-05	CcSEcCtD
Pramipexole—Paraesthesia—Epirubicin—prostate cancer	2.15e-05	5.48e-05	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—prostate cancer	2.14e-05	5.46e-05	CcSEcCtD
Pramipexole—Dyspnoea—Epirubicin—prostate cancer	2.13e-05	5.44e-05	CcSEcCtD
Pramipexole—Somnolence—Epirubicin—prostate cancer	2.13e-05	5.42e-05	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—prostate cancer	2.11e-05	5.38e-05	CcSEcCtD
Pramipexole—Nausea—Docetaxel—prostate cancer	2.11e-05	5.37e-05	CcSEcCtD
Pramipexole—Dyspepsia—Epirubicin—prostate cancer	2.11e-05	5.37e-05	CcSEcCtD
Pramipexole—Diarrhoea—Prednisone—prostate cancer	2.09e-05	5.34e-05	CcSEcCtD
Pramipexole—Decreased appetite—Epirubicin—prostate cancer	2.08e-05	5.3e-05	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—prostate cancer	2.07e-05	5.27e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Epirubicin—prostate cancer	2.07e-05	5.27e-05	CcSEcCtD
Pramipexole—Fatigue—Epirubicin—prostate cancer	2.06e-05	5.26e-05	CcSEcCtD
Pramipexole—Constipation—Epirubicin—prostate cancer	2.05e-05	5.22e-05	CcSEcCtD
Pramipexole—Pain—Epirubicin—prostate cancer	2.05e-05	5.22e-05	CcSEcCtD
Pramipexole—Nausea—Capecitabine—prostate cancer	2.04e-05	5.2e-05	CcSEcCtD
Pramipexole—Dizziness—Prednisone—prostate cancer	2.02e-05	5.16e-05	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.02e-05	5.14e-05	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—prostate cancer	2e-05	5.11e-05	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—prostate cancer	1.99e-05	5.07e-05	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—prostate cancer	1.97e-05	5.03e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Epirubicin—prostate cancer	1.97e-05	5.03e-05	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—prostate cancer	1.97e-05	5.02e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Epirubicin—prostate cancer	1.96e-05	4.99e-05	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—prostate cancer	1.95e-05	4.97e-05	CcSEcCtD
Pramipexole—Vomiting—Prednisone—prostate cancer	1.95e-05	4.96e-05	CcSEcCtD
Pramipexole—Rash—Prednisone—prostate cancer	1.93e-05	4.92e-05	CcSEcCtD
Pramipexole—Dermatitis—Prednisone—prostate cancer	1.93e-05	4.91e-05	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—prostate cancer	1.93e-05	4.91e-05	CcSEcCtD
Pramipexole—Headache—Prednisone—prostate cancer	1.92e-05	4.89e-05	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.91e-05	4.87e-05	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—prostate cancer	1.91e-05	4.87e-05	CcSEcCtD
Pramipexole—Urticaria—Epirubicin—prostate cancer	1.9e-05	4.85e-05	CcSEcCtD
Pramipexole—Pain—Doxorubicin—prostate cancer	1.89e-05	4.83e-05	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—prostate cancer	1.89e-05	4.83e-05	CcSEcCtD
Pramipexole—Abdominal pain—Epirubicin—prostate cancer	1.89e-05	4.82e-05	CcSEcCtD
Pramipexole—Body temperature increased—Epirubicin—prostate cancer	1.89e-05	4.82e-05	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—prostate cancer	1.83e-05	4.65e-05	CcSEcCtD
Pramipexole—Nausea—Prednisone—prostate cancer	1.82e-05	4.63e-05	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—prostate cancer	1.81e-05	4.62e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Epirubicin—prostate cancer	1.76e-05	4.49e-05	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—prostate cancer	1.76e-05	4.48e-05	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—prostate cancer	1.75e-05	4.46e-05	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—prostate cancer	1.75e-05	4.46e-05	CcSEcCtD
Pramipexole—Asthenia—Epirubicin—prostate cancer	1.72e-05	4.38e-05	CcSEcCtD
Pramipexole—Pruritus—Epirubicin—prostate cancer	1.69e-05	4.32e-05	CcSEcCtD
Pramipexole—Diarrhoea—Epirubicin—prostate cancer	1.64e-05	4.17e-05	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—prostate cancer	1.63e-05	4.16e-05	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—prostate cancer	1.59e-05	4.05e-05	CcSEcCtD
Pramipexole—Dizziness—Epirubicin—prostate cancer	1.58e-05	4.03e-05	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—prostate cancer	1.57e-05	3.99e-05	CcSEcCtD
Pramipexole—Vomiting—Epirubicin—prostate cancer	1.52e-05	3.88e-05	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—prostate cancer	1.52e-05	3.86e-05	CcSEcCtD
Pramipexole—Rash—Epirubicin—prostate cancer	1.51e-05	3.85e-05	CcSEcCtD
Pramipexole—Dermatitis—Epirubicin—prostate cancer	1.51e-05	3.84e-05	CcSEcCtD
Pramipexole—Headache—Epirubicin—prostate cancer	1.5e-05	3.82e-05	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—prostate cancer	1.46e-05	3.73e-05	CcSEcCtD
Pramipexole—Nausea—Epirubicin—prostate cancer	1.42e-05	3.62e-05	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—prostate cancer	1.41e-05	3.59e-05	CcSEcCtD
Pramipexole—Rash—Doxorubicin—prostate cancer	1.4e-05	3.56e-05	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—prostate cancer	1.4e-05	3.56e-05	CcSEcCtD
Pramipexole—Headache—Doxorubicin—prostate cancer	1.39e-05	3.54e-05	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—prostate cancer	1.32e-05	3.35e-05	CcSEcCtD
Pramipexole—HTR1D—Signaling Pathways—EGFR—prostate cancer	3.59e-06	2.63e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—prostate cancer	3.58e-06	2.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CB—prostate cancer	3.58e-06	2.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IGF1—prostate cancer	3.58e-06	2.62e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	3.58e-06	2.62e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NOS3—prostate cancer	3.57e-06	2.61e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	3.56e-06	2.61e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	3.56e-06	2.6e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SRC—prostate cancer	3.55e-06	2.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—prostate cancer	3.55e-06	2.6e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	3.54e-06	2.59e-05	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	3.54e-06	2.59e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—prostate cancer	3.54e-06	2.59e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCND1—prostate cancer	3.53e-06	2.59e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—prostate cancer	3.53e-06	2.58e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—JAK2—prostate cancer	3.52e-06	2.58e-05	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	3.52e-06	2.58e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—EGFR—prostate cancer	3.51e-06	2.57e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—prostate cancer	3.51e-06	2.57e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SRC—prostate cancer	3.5e-06	2.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	3.5e-06	2.56e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—prostate cancer	3.5e-06	2.56e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—prostate cancer	3.49e-06	2.55e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—EP300—prostate cancer	3.48e-06	2.55e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—prostate cancer	3.48e-06	2.55e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—prostate cancer	3.48e-06	2.55e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—JAK2—prostate cancer	3.47e-06	2.54e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—prostate cancer	3.47e-06	2.54e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	3.46e-06	2.53e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	3.46e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—prostate cancer	3.46e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—prostate cancer	3.46e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	3.45e-06	2.53e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MDM2—prostate cancer	3.44e-06	2.52e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	3.44e-06	2.52e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—prostate cancer	3.43e-06	2.51e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—prostate cancer	3.43e-06	2.51e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	3.42e-06	2.51e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	3.42e-06	2.5e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—prostate cancer	3.41e-06	2.5e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—prostate cancer	3.41e-06	2.5e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—prostate cancer	3.41e-06	2.5e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	3.4e-06	2.49e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	3.4e-06	2.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	3.4e-06	2.49e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—prostate cancer	3.39e-06	2.48e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—prostate cancer	3.39e-06	2.48e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ERBB2—prostate cancer	3.39e-06	2.48e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—prostate cancer	3.39e-06	2.48e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—prostate cancer	3.39e-06	2.48e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MDM2—prostate cancer	3.38e-06	2.48e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—prostate cancer	3.38e-06	2.47e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	3.38e-06	2.47e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—prostate cancer	3.38e-06	2.47e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—prostate cancer	3.37e-06	2.47e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—prostate cancer	3.37e-06	2.46e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	3.36e-06	2.46e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	3.36e-06	2.46e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—prostate cancer	3.35e-06	2.45e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ERBB2—prostate cancer	3.34e-06	2.44e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	3.33e-06	2.44e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—prostate cancer	3.32e-06	2.43e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—prostate cancer	3.32e-06	2.43e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—prostate cancer	3.31e-06	2.42e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—prostate cancer	3.3e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—prostate cancer	3.3e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	3.3e-06	2.42e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—prostate cancer	3.3e-06	2.41e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—prostate cancer	3.29e-06	2.41e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	3.29e-06	2.41e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—FGF2—prostate cancer	3.29e-06	2.41e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	3.28e-06	2.4e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—prostate cancer	3.28e-06	2.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	3.27e-06	2.39e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—prostate cancer	3.27e-06	2.39e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EP300—prostate cancer	3.25e-06	2.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NOS3—prostate cancer	3.25e-06	2.38e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—prostate cancer	3.22e-06	2.35e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—prostate cancer	3.21e-06	2.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—prostate cancer	3.21e-06	2.35e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—prostate cancer	3.2e-06	2.34e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	3.19e-06	2.34e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—prostate cancer	3.19e-06	2.33e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—prostate cancer	3.18e-06	2.33e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—prostate cancer	3.18e-06	2.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—prostate cancer	3.16e-06	2.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SRC—prostate cancer	3.16e-06	2.32e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—JAK2—prostate cancer	3.15e-06	2.31e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EP300—prostate cancer	3.14e-06	2.3e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—prostate cancer	3.14e-06	2.3e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1B—prostate cancer	3.14e-06	2.3e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—prostate cancer	3.13e-06	2.29e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EP300—prostate cancer	3.12e-06	2.29e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—prostate cancer	3.12e-06	2.28e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	3.12e-06	2.28e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—prostate cancer	3.11e-06	2.28e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	3.11e-06	2.28e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—prostate cancer	3.11e-06	2.27e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—prostate cancer	3.1e-06	2.27e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	3.09e-06	2.26e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	3.09e-06	2.26e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	3.08e-06	2.26e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MDM2—prostate cancer	3.08e-06	2.25e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—prostate cancer	3.08e-06	2.25e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—prostate cancer	3.07e-06	2.25e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—prostate cancer	3.07e-06	2.25e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—prostate cancer	3.06e-06	2.24e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	3.06e-06	2.24e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SRC—prostate cancer	3.05e-06	2.24e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—prostate cancer	3.05e-06	2.23e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	3.05e-06	2.23e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EP300—prostate cancer	3.04e-06	2.22e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SRC—prostate cancer	3.04e-06	2.22e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	3.04e-06	2.22e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—prostate cancer	3.03e-06	2.22e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—prostate cancer	3.02e-06	2.21e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—prostate cancer	3.01e-06	2.21e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—prostate cancer	3.01e-06	2.2e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—prostate cancer	3e-06	2.2e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—prostate cancer	3e-06	2.19e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	3e-06	2.19e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—prostate cancer	2.97e-06	2.18e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CTNNB1—prostate cancer	2.97e-06	2.17e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.96e-06	2.17e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SRC—prostate cancer	2.96e-06	2.16e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—EP300—prostate cancer	2.95e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—prostate cancer	2.95e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.95e-06	2.16e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—prostate cancer	2.95e-06	2.16e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—prostate cancer	2.94e-06	2.15e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.93e-06	2.14e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.92e-06	2.14e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—prostate cancer	2.91e-06	2.13e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—prostate cancer	2.9e-06	2.13e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—prostate cancer	2.9e-06	2.12e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1A—prostate cancer	2.9e-06	2.12e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—prostate cancer	2.89e-06	2.12e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.88e-06	2.11e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	2.88e-06	2.11e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.87e-06	2.1e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.86e-06	2.09e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.85e-06	2.09e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—prostate cancer	2.85e-06	2.09e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.85e-06	2.08e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—prostate cancer	2.84e-06	2.08e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	2.83e-06	2.07e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.82e-06	2.06e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.81e-06	2.06e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.78e-06	2.04e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.78e-06	2.03e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—prostate cancer	2.77e-06	2.03e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—prostate cancer	2.77e-06	2.03e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—prostate cancer	2.76e-06	2.02e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—prostate cancer	2.76e-06	2.02e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EP300—prostate cancer	2.76e-06	2.02e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.76e-06	2.02e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.75e-06	2.01e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.74e-06	2e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—prostate cancer	2.74e-06	2e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—prostate cancer	2.73e-06	2e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—prostate cancer	2.72e-06	1.99e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.72e-06	1.99e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EP300—prostate cancer	2.71e-06	1.99e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—prostate cancer	2.7e-06	1.98e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—prostate cancer	2.7e-06	1.98e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—prostate cancer	2.69e-06	1.97e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.68e-06	1.96e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SRC—prostate cancer	2.68e-06	1.96e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—prostate cancer	2.68e-06	1.96e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—prostate cancer	2.67e-06	1.95e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.66e-06	1.95e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—prostate cancer	2.66e-06	1.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.66e-06	1.94e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—prostate cancer	2.65e-06	1.94e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	2.64e-06	1.93e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SRC—prostate cancer	2.64e-06	1.93e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—prostate cancer	2.62e-06	1.92e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—prostate cancer	2.61e-06	1.91e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—prostate cancer	2.61e-06	1.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2.6e-06	1.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	2.59e-06	1.9e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—prostate cancer	2.59e-06	1.9e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—prostate cancer	2.59e-06	1.89e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—prostate cancer	2.59e-06	1.89e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—prostate cancer	2.58e-06	1.89e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—prostate cancer	2.58e-06	1.89e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—prostate cancer	2.57e-06	1.88e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—prostate cancer	2.54e-06	1.86e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—prostate cancer	2.54e-06	1.86e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—prostate cancer	2.54e-06	1.86e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—prostate cancer	2.53e-06	1.85e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2.53e-06	1.85e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.52e-06	1.84e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—prostate cancer	2.49e-06	1.82e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EP300—prostate cancer	2.47e-06	1.81e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—prostate cancer	2.45e-06	1.79e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—prostate cancer	2.45e-06	1.79e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	2.41e-06	1.76e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—prostate cancer	2.4e-06	1.76e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SRC—prostate cancer	2.4e-06	1.76e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—prostate cancer	2.4e-06	1.75e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—prostate cancer	2.39e-06	1.75e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—prostate cancer	2.36e-06	1.73e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—prostate cancer	2.36e-06	1.73e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—prostate cancer	2.36e-06	1.73e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—prostate cancer	2.35e-06	1.72e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—prostate cancer	2.34e-06	1.71e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	2.34e-06	1.71e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—prostate cancer	2.33e-06	1.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	2.32e-06	1.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—prostate cancer	2.32e-06	1.69e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—prostate cancer	2.31e-06	1.69e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	2.31e-06	1.69e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—prostate cancer	2.26e-06	1.65e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	2.25e-06	1.65e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—prostate cancer	2.25e-06	1.65e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—prostate cancer	2.24e-06	1.64e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—prostate cancer	2.22e-06	1.63e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—prostate cancer	2.21e-06	1.62e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—prostate cancer	2.2e-06	1.61e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—prostate cancer	2.18e-06	1.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—prostate cancer	2.18e-06	1.6e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—prostate cancer	2.18e-06	1.59e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—prostate cancer	2.18e-06	1.59e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—prostate cancer	2.15e-06	1.57e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	2.15e-06	1.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—prostate cancer	2.13e-06	1.56e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—prostate cancer	2.1e-06	1.54e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—prostate cancer	2.1e-06	1.54e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—prostate cancer	2.06e-06	1.51e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—prostate cancer	2.05e-06	1.5e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—prostate cancer	2.04e-06	1.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	2.01e-06	1.47e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.99e-06	1.46e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.99e-06	1.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—prostate cancer	1.97e-06	1.44e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.97e-06	1.44e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—prostate cancer	1.94e-06	1.42e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.9e-06	1.39e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.89e-06	1.38e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.84e-06	1.34e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.83e-06	1.34e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—prostate cancer	1.81e-06	1.32e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—prostate cancer	1.78e-06	1.31e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—prostate cancer	1.78e-06	1.3e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.77e-06	1.29e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—prostate cancer	1.67e-06	1.22e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.64e-06	1.2e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.62e-06	1.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.49e-06	1.09e-05	CbGpPWpGaD
